Thomas E. Olencki DO

Oncology•Columbus, OH

Professor, Internal Medicine, Ohio State University College of Medicine

Join to View Full Profile

320 W 10th AveColumbus, OhioColumbus, OH 43210
Phone+1 614-293-9868
Fax+1 614-293-7525

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1984 - 1985
Corewell Health East Beaumont (Royal Oak)Residency, Internal Medicine, 1981 - 1984
Michigan State University College of Osteopathic MedicineClass of 1980

Certifications & Licensure

OH State License 1993 - 2021

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
Withdrawn
Phase 2
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Start of enrollment: 2007 Nov 01
Completed
Phase 2
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer Start of enrollment: 2008 Feb 01
Terminated
Phase 1
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Start of enrollment: 2008 Aug 01
Completed
Phase 2
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
Completed
Phase 2
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Start of enrollment: 2012 Nov 09
Completed
Phase 1
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Start of enrollment: 2013 Jul 31
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.
Mark Damante, Kristin Huntoon, David Gibbs, Dante Pezzutti, Thomas Olencki
Neurosurgical Focus. 2023-08-01
9 citations
Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy.
Shaheer Khan, Jose Lutzky, Alexander N Shoushtari, Joanne Jeter, Brian Marr
Frontiers in Oncology. 2022-01-01
3 citations
Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy.
Kristin Huntoon, Mark Damante, Joshua Wang, Thomas Olencki, J. Bradley Elder
Current Problems in Cancer. 2021-11-18

Journal Articles

Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...
Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer

Authored Content

Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018

Professional Memberships

American Osteopathic Association - AOA
Member
American College of Physicians - ACP
Member